FRES

Fresh2 Group Limited Sponsored ADR Class A · NASDAQ

Performance

-24.73%

1W

+2.08%

1M

-34.63%

3M

-53.16%

6M

-58.13%

YTD

-90.17%

1Y

Profile

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.

Technical Analysis of FRES 2024-04-05

Overview:

In the last 5 trading days, FRES stock has shown a downward trend in price, with decreasing closing prices and declining volume. The moving averages (MA) and exponential moving averages (EMA) have also been trending downwards, indicating a bearish sentiment. Momentum indicators like the Relative Strength Index (RSI) and Stochastic Osci...

See more ...